Clinical Trials Browser

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02341014 2024-04-04

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

Phase 1/2 Completed

27 enrolled 13 charts

Lymphoid

Lymphoma, Recurrence, Lymphoma, T-Cell

NCT01947140 2022-11-23

PDX+Romi

Phase 1/2 Completed

57 enrolled

DermatologicLymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03770000 2022-10-28

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

Phase 1/2 Completed

33 enrolled 13 charts

Lymphoid

Lymphoma, T-Cell

NCT03141203 2022-05-18

RomiCar

Phase 1/2 Completed

50 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03161223 2022-03-31

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

Phase 1/2 Recruiting

148 enrolled

Lymphoid

Lymphoma, T-Cell

NCT03547700 2021-01-19

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

Phase 1/2 Active not recruiting

11 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT01456039 2019-02-11

A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)

Phase 1/2 Completed

51 enrolled 34 charts

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT01979276 2018-06-06

Romi Poma

Phase 1/2 Terminated

4 enrolled 10 charts

Plasma cell

Multiple Myeloma

NCT00085540 2017-01-02

FR901228 in Treating Patients With Recurrent High-Grade Gliomas

Phase 1/2 Completed

50 enrolled 6 charts

CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Gliosarcoma

NCT02281279 2016-08-11

Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

Phase 1/2 Withdrawn

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma

NCT01280526 2014-05-22

Ro-CHOP

Phase 1/2 Completed

37 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT00431990 2011-08-12

A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

Phase 1/2 Unknown

40 enrolled

Plasma cell

Multiple Myeloma

Clinical Trials

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

FIL_PTCL13

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

SEPION

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

PDX+Romi

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

RomiCar

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)

Romi Poma

FR901228 in Treating Patients With Recurrent High-Grade Gliomas

Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

Ro-CHOP

A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma